(1)

Early life vitamin D depletion and mechanical loading determine methylation changes in the RXRA, Runx2 and osterix promoters in mice

ba0007oc5 | (1)

Low birthweight is associated with poorer limb muscle mass and grip strength in middle age: findings from the UK Biobank Imaging Enhancement

ba0007oc6 | (1)

Anthropometric characteristics of pediatric patients with hypophosphatasia: data from the Global Hypophosphatasia Patient Registry

ba0007oc7 | (1)

Comparison of zoledronate and pamidronate in children with skeletal disorders: Short term safety experience from a single institution

ba0007oc8 | (1)

Bisphosphonate improves hip range of motion and pain but not femoral head sphericity: A multicentre, randomized clinical trial of children with Perthes disease

ba0007oc9 | (1)

Efficacy and safety of intravenous zoledronic acid for the treatment of pediatric glucocorticoid-induced osteoporosis: An international, randomized placebo-controlled trial

ba0007oc10 | (1)

Next-generation antibody-guided enzyme replacement therapy for lysosomal storage diseases

ba0007oc11 | (1)

Targeting adeno-associated viral vectors to fractures and the skeleton

ba0007oc12 | (1)

Combination treatment of a novel activin receptor IIB ligand trap and zoledronate improves muscle and bone proprieties in a mouse model of osteogenesis imperfecta

ba0007oc13 | (1)

Analysis of osteogenesis imperfecta in pathology and the effects of 4-phenylbutyric acid using patient-derived fibroblasts and induced pluripotent stem cells

ba0007oc14 | (1)

Burosumab resulted in greater improvement in clinical outcomes than continuation with conventional therapy in younger (1-4 years-old) and older (5-12 years-old) children with X-linked hypophosphatemia

ba0007oc15 | (1)

Sustained efficacy and safety of burosumab, a fully human anti-FGF23 monoclonal antibody, in children and early adolescents with X-linked hypophosphatemia

ba0007oc16 | (1)

A natural history study of generalized arterial calcification of infancy (GACI) and autosomal recessive hypophosphatemic rickets (ARHR2) due to ENPP1 or ABCC6 deficiency: interim analysis

ba0007oc17 | (1)

Growth curves for children with X-linked hypophosphatemia

ba0007oc18 | (1)

Developing a human-mouse hybrid model of osteogenesis imperfecta for investigating new therapies for children

ba0007oc19 | (1)

Altered 3 hydroxylation complex in bone homeostasis

ba0007oc20 | (1)

Identifying the role of NBAS in bone fragility using zebrafish and exploring therapeutic targets to reverse NBAS activity

ba0007oc21 | (1)

New mouse model with IFITM5 S42L for atypical type VI osteogenesis imperfecta

ba0007oc22 | (1)

Bone tissue phenotyping reveals increased matrix mineralization, elevated osteocyte lacunar density and altered vascularity in a new OI mouse model carrying a leucine substitution for the BRIL p.Serine42 residue

ba0007oc23 | (1)

Effects of the FGF2 aptamer on growth plate cartilage development of achondroplasia patient-specific iPS cells in a xenograft model

ba0007oc24 | (1)

TA-46, a recombinant soluble FGFR3 receptor for the treatment of achondroplasia, is safe and well-tolerated in healthy volunteers

ba0007oc25 | (1)

TransCon CNP: Potential for a once weekly novel therapy in children with achondroplasia

ba0007oc26 | (1)

[18F] NaF PET/CT the first tool to diagnose chronic activity in FOP at all ages?

ba0007oc27 | (1)

Bone Abstracts

9th International Conference on Children's Bone Health

Oral Communications

Association between age at puberty and bone accrual up to 25 years-old

Adolescent pregnancy and bone density in premenopausal women

Osteocyte lacunae characteristics in healthy children

Early life vitamin D depletion and mechanical loading determine methylation changes in the RXRA, Runx2 and osterix promoters in mice

Low birthweight is associated with poorer limb muscle mass and grip strength in middle age: findings from the UK Biobank Imaging Enhancement

Anthropometric characteristics of pediatric patients with hypophosphatasia: data from the Global Hypophosphatasia Patient Registry

Comparison of zoledronate and pamidronate in children with skeletal disorders: Short term safety experience from a single institution

Bisphosphonate improves hip range of motion and pain but not femoral head sphericity: A multicentre, randomized clinical trial of children with Perthes disease

Efficacy and safety of intravenous zoledronic acid for the treatment of pediatric glucocorticoid-induced osteoporosis: An international, randomized placebo-controlled trial

Next-generation antibody-guided enzyme replacement therapy for lysosomal storage diseases

Targeting adeno-associated viral vectors to fractures and the skeleton

Combination treatment of a novel activin receptor IIB ligand trap and zoledronate improves muscle and bone proprieties in a mouse model of osteogenesis imperfecta

Analysis of osteogenesis imperfecta in pathology and the effects of 4-phenylbutyric acid using patient-derived fibroblasts and induced pluripotent stem cells

Burosumab resulted in greater improvement in clinical outcomes than continuation with conventional therapy in younger (1-4 years-old) and older (5-12 years-old) children with X-linked hypophosphatemia

Sustained efficacy and safety of burosumab, a fully human anti-FGF23 monoclonal antibody, in children and early adolescents with X-linked hypophosphatemia

A natural history study of generalized arterial calcification of infancy (GACI) and autosomal recessive hypophosphatemic rickets (ARHR2) due to ENPP1 or ABCC6 deficiency: interim analysis

Growth curves for children with X-linked hypophosphatemia

Developing a human-mouse hybrid model of osteogenesis imperfecta for investigating new therapies for children

Altered 3 hydroxylation complex in bone homeostasis

Identifying the role of NBAS in bone fragility using zebrafish and exploring therapeutic targets to reverse NBAS activity

New mouse model with IFITM5 S42L for atypical type VI osteogenesis imperfecta

Bone tissue phenotyping reveals increased matrix mineralization, elevated osteocyte lacunar density and altered vascularity in a new OI mouse model carrying a leucine substitution for the BRIL p.Serine42 residue

Effects of the FGF2 aptamer on growth plate cartilage development of achondroplasia patient-specific iPS cells in a xenograft model

TA-46, a recombinant soluble FGFR3 receptor for the treatment of achondroplasia, is safe and well-tolerated in healthy volunteers

TransCon CNP: Potential for a once weekly novel therapy in children with achondroplasia

[18F] NaF PET/CT the first tool to diagnose chronic activity in FOP at all ages?

Palovarotene inhibits the development of new heterotopic ossification in fibrodysplasia ossificans progressiva (FOP)

BiosciAbstracts